{"id":330835,"date":"2026-08-08T10:36:10","date_gmt":"2026-08-08T10:36:10","guid":{"rendered":"https:\/\/www.europesays.com\/se\/330835\/"},"modified":"2026-08-08T10:36:10","modified_gmt":"2026-08-08T10:36:10","slug":"bank-of-america-lagger-miljarder-pa-ozempic","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/330835\/","title":{"rendered":"Bank of America l\u00e4gger miljarder p\u00e5 Ozempic"},"content":{"rendered":"<p>Publicerad 8 aug 2026 kl 11.44<\/p>\n<p>F\u00f6retaget spenderar miljarder f\u00f6r att de anst\u00e4llda ska g\u00e5 ner i vikt.<\/p>\n<p>Kostnaden har g\u00e5tt fr\u00e5n noll till hundra p\u00e5 n\u00e5gra \u00e5r.<\/p>\n<p>\u2013 Vi ser en stor p\u00e5verkan p\u00e5 v\u00e5ra anst\u00e4llda, s\u00e4ger Brian Moynihan, vd f\u00f6r Bank of America, till <a href=\"https:\/\/www.cnbc.com\/2026\/08\/05\/bank-of-america-ceo-glp-1-drugs-cost.html\" rel=\"nofollow noopener\" target=\"_blank\">CNBC<\/a>.<\/p>\n<p><img   alt=\"\"\/><\/p>\n<p>Brian Moynihan \u00e4r vd f\u00f6r Bank of America.<\/p>\n<p>Foto: Monika Graff\/UPI\/Shutterstock \/ TT NYHETSBYR\u00c5N<\/p>\n<p>\u00d6ppna bild i helsk\u00e4rm<img loading=\"lazy\"   alt=\"\"\/><\/p>\n<p>Ozempic \u00e4r ett receptbelagt l\u00e4kemedel som anv\u00e4nds f\u00f6r att behandla typ 2-diabetes men kan \u00e4ven anv\u00e4ndas f\u00f6r viktnedg\u00e5ng.<\/p>\n<p>Foto: Mohammed_Al_Ali \/ Shutterstock<\/p>\n<p>\u00d6ppna bild i helsk\u00e4rmArtikeln i korthet<\/p>\n<p> Bank of America l\u00e4gger omkring 2 miljarder kronor om \u00e5ret p\u00e5 viktminskningsl\u00e4kemedel till anst\u00e4llda.<\/p>\n<p> L\u00e4kemedlen st\u00e5r nu f\u00f6r cirka 13 procent av bankens totala sjukv\u00e5rdskostnader.<\/p>\n<p> Vd:n Brian Moynihan beskriver satsningen som en l\u00e5ngsiktig investering i personalens h\u00e4lsa<\/p>\n<p>Visa mer<\/p>\n<p>Bank of America g\u00f6r en storsatsning f\u00f6r att deras anst\u00e4llda ska bli mer h\u00e4lsosamma, skriver CNBC. Nu ber\u00e4ttar bankens vd, Brian Moynihan, att banken \u00e5rligen l\u00e4gger drygt 2 miljarder kronor p\u00e5 viktminskningsl\u00e4kemedel.<\/p>\n<p>Varje \u00e5r l\u00e4gger f\u00f6retaget runt 20,8 miljarder kronor p\u00e5 sjukv\u00e5rd f\u00f6r sina cirka 211 000 anst\u00e4llda och viktmediciner som <a href=\"https:\/\/www.expressen.se\/tagg\/organization\/ozempic\/\" class=\"\" rel=\"nofollow noopener\" target=\"_blank\">Ozempic<\/a> st\u00e5r f\u00f6r 13 procent av sjukv\u00e5rdskostnaderna. Brian Moynihan menar att den snabbt stigande kostnaden \u00e4r en v\u00e4rdefull investering i personalen. F\u00f6r fem-sex \u00e5r sedan l\u00e5g kostnaden p\u00e5 noll.<\/p>\n<p>Ut\u00f6ver att f\u00f6rse sina anst\u00e4llda med l\u00e4kemedlet erbjuder f\u00f6retaget \u00e4ven h\u00e4lsocoachning. Bank of America \u00e4r USA:s n\u00e4st st\u00f6rsta bank, r\u00e4knat i tillg\u00e5ngar, och enligt Brian Moynihan bidrar deras storlek till att de kan f\u00e5 l\u00e4gre priser p\u00e5 viktminskningsmedicinerna.\u00a0<\/p>\n<p>\u2013 Tro mig, vi pressar alla p\u00e5 pris och f\u00f6rs\u00f6ker f\u00e5 det s\u00e5 billigt som m\u00f6jligt.<\/p>\n<p>\u2013 V\u00e5r uppfattning \u00e4r att det \u00e4r en bra investering, i och med de l\u00e5ngsiktiga h\u00e4lsof\u00f6rdelarna och att det kanske kommer fler kortsiktiga f\u00f6rdelar, s\u00e4ger Brian Moynihan.<\/p>\n<p>En tredjedel erbjuder ers\u00e4ttning<\/p>\n<p>Drygt 36 procent av arbetsgivarna i USA erbjuder ers\u00e4ttning f\u00f6r olika typer av GLP-1-l\u00e4kemedel som anv\u00e4nds f\u00f6r att behandla diabetes och till viktnedg\u00e5ng, skriver CNBC.<\/p>\n<p>L\u00e4kemedelsbolagen som tillverkar l\u00e4kemedlen har f\u00f6rs\u00f6kt f\u00e5 fler f\u00f6retag att inkludera dem i sina sjukv\u00e5rdsf\u00f6rs\u00e4kringar. Eli Lilly lanserade i mars ett nytt program d\u00e4r arbetsgivare f\u00e5r st\u00f6rre flexibilitet i hur de ers\u00e4tter behandlingar och dessutom kan k\u00f6pa l\u00e4kemedlet i st\u00f6rre volymer till ett l\u00e4gre pris.<\/p>\n","protected":false},"excerpt":{"rendered":"Publicerad 8 aug 2026 kl 11.44 F\u00f6retaget spenderar miljarder f\u00f6r att de anst\u00e4llda ska g\u00e5 ner i vikt.&hellip;\n","protected":false},"author":2,"featured_media":330836,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,444,34,2298,31,33,32,30,51],"class_list":["post-330835","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-ozempic","tag-se","tag-sjukvard","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-varlden"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/117059451947043260","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/330835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=330835"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/330835\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/330836"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=330835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=330835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=330835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}